|
[1]BEUERS U, GERSHWIN ME, GISH RG, et al.Changing nomenclature for PBC:from‘cirrhosis’to‘cholangitis’[J].Gut, 2015, 64 (11) :1671-1672.
|
|
[2]CARBONE M, MELLS GF, PELLS G, et al.Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid[J].Gastorenterology, 2013, 144 (3) :560-569.
|
|
[3]MELLS GF, FLOYD JA, MORLEY KI, et al.Genome-wide association study identifies 12 new susceptibility loci for primary biliary cirrhosis[J].Nat Genet, 2011, 43 (4) :329-332.
|
|
[4]HIRSCHFIELD GM, GERSHWIN ME, STRAUSS R, et al.Ustekinumab for patients with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid:a proof-of-concept study[J].Hepatology, 2016, 64 (1) :189-199.
|
|
[5]AFFORD SC, AHMED-CHOUDHURY J, RANDHAWA S, et al.CD40 activation-induced, Fas-dependent apoptosis and NF-kappa B/AP-1 signaling in human intrahepatic biliary epithelial cells[J].FASEB J, 2001, 15 (13) :2345-2354.
|
|
[6]MYERS RP, SWAIN MG, LEE SS, et al.B-cell depletion with rituximab in patients with primary biliary cirrhosis refractory to ursodeoxycholic acid[J].Am J Gastroenterol, 2013, 108 (6) :933-941.
|
|
[7]LENS S, LEOZ M, NAZAL L, et al.Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid[J].Liver Int, 2014, 34 (2) :197-203.
|
|
[8]NEVENS F, ANDREONE P, MAZZELLA G, et al.A placebocontrolled trial of obeticholic acid in primary billary cholangitis[J].N Engl J Med, 2016, 375 (7) :631-643.
|
|
[9]LIASKOU E, HIRSCHFIELD GM, GERSHWIN ME, et al.Mechanisms of tissue injury in autoimmune liver diseases[J].Semin Immunopathol, 2014, 36 (5) :553-568.
|
|
[10]KITA H, LIAN ZX, van de WATER J, et al.Identification of HLA-A2-restricted CD8+cytotoxic T-cell responses in primary biliary cirrhosis:T-cell activation is augmented by immune complexes cross presented by dendritic cells[J].J Exp Med, 2002, 195 (1) :113-123.
|
|
[11]MAILLETTE de BUY WENNIGER LJ, OUDE ELFERINK RP, BEUERS U.Molecular targets for the treatment of fibrosing cholangiopathies[J].Clin Pharmacol Ther, 2012, 92 (3) :381-387.
|
|
[12]BEUERS U, NATHANSON MH, ISALES CM, et al.Tauroursodeoxycholic acid stimulates hepatocellular exocytosis and mobilizes extracellular Ca++mechanisms defective in cholestasis[J].J Clin Invest, 1993, 92 (6) :2984-2993.
|
|
[13]BEUERS U.β1-Integrin is a long-sought sensor for tauroursodeoxycholic acid[J].Hepatology, 2013, 57 (3) :867-869.
|
|
[14]HOHENESTER S, WENNIGER LM, PAULUSMA CC, et al.Abiliary HCO-3umbrella constitutes a protective mechanism against bile acid-induced injury in human cholangiocytes[J].Hepatology, 2012, 55 (1) :173-183.
|
|
[15]BAGHDASARYAN A, CLAUDEL T, GUMHOLD J, et al.Dual farnesoid X receptor/TGR5 agonist INT-767 reduces liver injury in the Mdr2-/- (Abcb4-/-) mouse cholangiopathy model by promoting biliary HCO3-output[J].Hepatology, 2011, 54 (4) :1303-1312.
|
|
[16]GHONEM NS, ANANTHANARAYANAN M, SOROKA CJ, et al.Peroxisome proliferator-activated receptor alpha activates human multidrug resistance transporter 3/ATP-binding cassette protein subfamily B4 transcription and increases rat biliary phosphatidylcholine secretion[J].Hepatology, 2014, 59 (3) :1030-1042.
|
|
[17]BYUN HO, LEE YK, KIM JM, et al.From cell senescence to age-related diseases:differential mechanisms of action of senescence-associated secretory phenotypes[J].BMB Rep, 2015, 48 (10) :549-558.
|
|
[18]WANG Q, DAI X, YANG W, et al.Caffeine protects against alcohol-induced liver fibrosis by dampening the c AMP/PKA/CREBpathway in rat hepatic stellate cells[J].Int Immunopharmacol, 2015, 25 (2) :340-352.
|
|
[19]LIU Z, YI J, YE R, et al.miR-144 regulates transforming growth factor-β1 iduced hepatic stellate cell activation in human fibrotic liver[J].Int J Clin Exp Pathol, 2015, 8 (4) :3994-4000.
|
|
[20]IWAISAKO K, JIANG C, ZHANG M, et al.Origin of myofibroblasts in the fibrotic liver in mice[J].Proc Natl Acad Sci USA, 2014, 111 (32) :e3297-e3305.
|
|
[21]POPOV Y, PATSENKER E, FICKERT P, et al.Mdr2 (Abcb4) -/-mice spontaneously develop severe biliary fibrosis via massive dysregulation of pro-and antifibrogenic genes[J].J Hepatol, 2005, 43 (6) :1045-1054.
|
|
[22]POPOV Y, PATSENKER E, STICKEL F, et al.Integrinαvβ6 is a marker of the progression of biliary and portal liver fibrosis and a novel target for antifibrotic therapies[J].J Hepatol, 2008, 48 (3) :453-464.
|
|
[23]PENG ZW, IKENAGA N, LIU SB, et al.Integrinαvβ6 critically regulates hepatic progenitor cell function and promotes ductular reaction, fibrosis, and tumorigenesis[J].Hepatology, 2016, 63 (1) :217-232.
|
|
[24]POUPON R.Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases:an overview of their mechanisms of action[J].Clin Res Hepatol Gastroenterol, 2012, 36 (Suppl 1) :s3-s12.
|
|
[25]SOMBETZKI M, FUCHS CD, FICKERT P, et al.24-nor-ursodeoxycholic acid ameliorates inflammatory response and liver fibrosis in a murine model of hepatic schistosomiasis[J].J Hepatol, 2015, 62 (4) :871-878.
|
|
[26]NEVENS F, ANDREONE P, MAZZELLA G, et al.The first primary biliary cirrhosis (PBC) phase 3 trial in two decades-an international study of the FXR agonist obeticholic acid in PBC patients[J].J Hepatol, 2014, 60 (1) :s525-s526.
|
|
[27]HIRSCHFIELD GM, MASON A, LUKETIC V, et al.Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid[J].Gastroenterology, 2015, 148 (4) :751-761.
|
|
[28]BEUERS U, KREMER AE, BOLIER R, et al.Pruritus in cholestasis:facts and fiction[J].Hepatology, 2014, 60 (1) :399-407.
|
|
[29]LECKIE P, TRITTO G, MOOKERJEE R, et al.'Out-patient'albumin dialysis for cholestatic patients with intractable pruritus[J].Aliment Pharmacol Ther, 2012, 35 (6) :696-704.
|
|
[30]KREMER AE, NAMER B, BOLIER R, et al.Pathogenesis and management of pruritus in PBC and PSC[J].Dig Dis, 2015, 33 (Suppl 2) :164-175.
|
|
[31]US National Library of Medicine.Clinical Trials.gov[EB/OL].2014, https://clinicaltrials.gov/ct2/show/NCT01904058.
|
|
[32]US National Library of Medicine.Clinical Trials.gov[EB/OL].2014, https://clinicaltrials.gov/ct2/show/NCT01899703.
|
|
[33]KREMER AE, DIJK R, LECKIE P, et al.Serum autotaxin is increased in pruritus of cholestasis, but not of other origin and responds to therapeutic interventions[J].Hepatology, 2012, 56 (4) :1391-1400.
|
|
[34]ALEMI F, KWON E, POOLE DP, et al.The TGR5 receptor mediated bile acid-induce itch and analgesia[J].J Clin Invest, 2013, 123 (4) :1513-1530.
|
|
[35]KEITEL V, REICH M, HAUSSINGER D, et al.TGR5:pathogenetic role and/or therapeutic target in fibrosing cholangitis?[J].Clin Rev Allergy Immunol, 2015, 48 (2-3) :218-225.
|
|
[36]JOPSON L, JONES DE.Fatigue in primary biliary cirrhosis:prevalence, pathogenesis and management[J].Dig Dis, 2015, 33 (Suppl 2) :109-114.
|
|
[37]D'MELLO C, RIAZI K, LE T, et al.P-selectin-mediated monocyte-cerebral endothelium adhesive interactions link peripheral organ inflammation to sickness behaviors[J].J Neurosci, 2013, 33 (37) :14878-14888.
|
|
[38]HOLLINGSWORTH KG, JONES DE, TAYLOR R, et al.Impaired cerebral autoregulation in primary biliary cirrhosis:implications for the pathogenesis of cognitive decline[J].Liver Int, 2010, 30 (6) :878-885.
|
|
[39]DIONISIO PA, AMARAL JD, RIBEIRO MF, et al.Amyloid-βpathology is attenuated by tauroursodeoxycholic acid treatment in APP/PS1 mice after disease onset[J].Neurobiol Aging, 2015, 36 (1) :228-240.
|
|
[40]HOLLINGSWORTH KG, NEWTON JL, TAYLOR R, et al.Pilot study of peripheral muscle function in primary biliary cirrhosis:potential implications for fatigue pathogenesis[J].Clin Gastroenterol Hepatol, 2008, 6 (9) :1041-1048.
|
DownLoad: